This pilot study investigates the sero-conversion rates of hepatitis B vaccinated individuals. The study was completed at a community clinic in Laguna Beach, California, where 100 predominantly white male individuals who were all vaccinated for hepatitis B were tested for sero-conversion. The purpose of this pilot study was to examine if the hepatitis B sero-conversion rates in a small sample of subjects reflected that of the published data, regardless of HIV status, after a hepatitis B vaccination series was completed, while following strict vaccine protocols. The theoretical framework for this study is focused on evidence-based practice, which drives practice to integrate new research into clinical protocols. Two frameworks were implemented first the Academic Center for Evidenced-based practice (ACE) Star Model of Knowledge Transformation, and the Awareness-to-Adherence model; both of which will be applied in order for practitioners to adopt immunization recommendations. This pilot study was conducted through a non-experimental, correlational cross sectional design. This design was used to evaluate the sero-conversion rates of a subject receiving a primary vaccine series of hepatitis B and who was hepatitis B naïve. Manufacturer published rates of sero-conversion are between 80% and 95%, depending upon the population studied. The results of the study demonstrated that sero-conversion rates were similar, but not as high as reported by the manufactures of the Hepatitis B vaccines. The data demonstrated that in HIV negative men (n=50), who received the 3 dose regimen, 78.6% sero-converted, and the sero-conversion rates of the HIV positive men was (n=48) 77%. This data is important with regard to current vaccine practice in all individuals who are vaccinated against hepatitis B. This includes healthcare workers, the immune-compromised and high-risk general populat